Navigation Links
Vermillion Reports Second Quarter 2012 Results
Date:8/14/2012

of a standardized triage protocol using OVA1 for all ovarian malignancies, which includes the most curable early-stage cases and a broad range of subtypes. So, this study lends robust support for further expanding payer coverage of the test, as well as updating current medical guidelines.

"As we begin the second half of 2012, we remain focused on our key initiatives. In addition to advancing our product discovery pipeline, these initiatives involve supporting further clinical research for OVA1, broadening its support by key opinion leaders, and expanding payer coverage. We're confident this will lead to increased clinical usage and, moreover, advance OVA1 toward becoming the standard of care in the diagnosis of ovarian cancer. We expect 4,100-4,400 OVA1 tests to be performed in the third quarter of 2012. As these numbers reflect, OVA1 is still in its early stage of adoption. However, as the results from our broad efforts begin to converge, they are setting the stage for strong growth in fiscal 2013."

CEO Succession Plan
As previously announced, the company's board has formed a succession committee of independent directors to oversee the process of identifying and selecting a new CEO. It has also retained a leading executive search firm with experience in CEO transitions to advise the board on potential candidates. According to Bruce Huebner, company director and chair of the succession committee: "We have met with a number of impressive potential candidates and expect to identify a successor with the ability and experience to take advantage of our tremendous opportunities in the ovarian cancer diagnostics market, as well as continue to develop Vermillion's pipeline of new products.

"Given the amount of interest and our goal of assuring we select the correct candidate, we have extended the timeframe to complete our search from September to October 2012. Gail will continue in her role until the new CEO is named, and then will become a strateg
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
6. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
8. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
9. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... Pa. , Jan. 14, 2014 Dynamic Healthcare Services, ... announced today that it acquired Progressive Home Medical Equipment, Inc. ... 7, 2014. The terms of the acquisition were not disclosed. ... equipment ("DME") company providing a wide range of sleep, mobility, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... May 15, 2012  Cardium Therapeutics (NYSE Amex: ... UK-based Angel Biomedical Limited, a subsidiary of Angel ... contract manufacturer, covering the manufacture of formulated collagen ... for marketing by the U.S. Food and Drug ...
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , ... treatment and diagnosis of cancer, today announced that ... a U.S. multi-center Phase 1b dose-escalation trial of ... cancer patients with advanced solid tumors.  The first ...
Cached Medicine Technology:Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 2Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 3Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 4Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 5Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion 6Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 2Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 3Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic 4
(Date:4/18/2014)... (April 21, 2014) -- A group of scientists ... and the Sanders-Brown Center on Aging has found ... and neuropsychological function in Parkinson,s disease (PD). ... , the study, which assessed cognitive function in ... the dopamine replacement therapy commonly used to treat ...
(Date:4/18/2014)... The Gerontologist reports that among older Christians, ... in anxiety about death and increases in life satisfaction, ... particular, listening to gospel music is associated with a ... sense of control. , These associations are similar for ... both low- and high-socioeconomic status. , The article, titled ...
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... new study in the American Journal of Preventive ... reveals a recurring pattern that could be leveraged to ... San Diego State University, the Santa Fe Institute, Johns ... searches (searches that included the term healthy and were ... from 2005 to 2012. They found that on average, ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2
... Hopkins and elsewhere report what is believed to be ... inflammation of heart tissue and the subsequent damage leading ... latest findings from the Multiethnic Study of Atherosclerosis (MESA), ... the Journal of the American College of Cardiology, appear ...
... at Mattel Children,s Hospital UCLA have found that low-dose antidepressant ... adolescents suffering from irritable bowel syndrome, or IBS. ... students and 14 percent of high school kids in the ... the May issue of the peer-reviewed Journal of Pediatrics, is ...
... WASHINGTON, May 1 Speaker Nancy Pelosi today,released ... Information,Nondiscrimination Act, which the House passed this afternoon ... bill, which would prohibit health,insurance companies and employers ... test results, now goes to the President,s desk ...
... said today that there are more than 36,000 uninsured ... whom are on a waiting,list to receive health care ... a plan to help them gain access to health ... live with the,very real fear that a sudden illness ...
... Courage Center has received a,one-year grant of $150,000 ... to,support The Bridge to Independence. This coordinated campaign ... children with disabilities,through effective grassroots community organizing, policy ... leading member of the Minnesota Consortium of Citizens ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... present key scientific data on its Attention Deficit ... system and the investigational non-stimulant treatment under FDA ... Association (APA) annual meeting to be held May ...
Cached Medicine News:Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Antidepressant found to alleviate symptoms of irritable bowel syndrome in adolescents 2Health News:Pelosi: 'Genetic Information Nondiscrimination Act Will Protect Americans from Misuse of Genetic Information' 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 2Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 3Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 4Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 5Health News:Governor Rendell Says Passage of PA ABC Would Help More Than 36,000 Uninsured Citizens Living in the Lehigh Valley 6Health News:Courage Center Receives $150,000 Grant From Minneapolis Foundation 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
Medicine Products: